Preprint Article Version 1 This version is not peer-reviewed

Gene Expression Comparison Between the Lymph Node-Positive and Negative Reveals a Peculiar Immune-microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study

Version 1 : Received: 22 June 2019 / Approved: 22 June 2019 / Online: 22 June 2019 (16:50:32 CEST)

How to cite: Argentiero, A.; De Summa, S.; Di Fonte, R.; Iacobazzi, R.M.; Porcelli, L.; da via, M.C.; Brunetti, O.; Azzariti, A.; Silvestris, N.; SOLIMANDO, A.G. Gene Expression Comparison Between the Lymph Node-Positive and Negative Reveals a Peculiar Immune-microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study. Preprints 2019, 2019060228 (doi: 10.20944/preprints201906.0228.v1). Argentiero, A.; De Summa, S.; Di Fonte, R.; Iacobazzi, R.M.; Porcelli, L.; da via, M.C.; Brunetti, O.; Azzariti, A.; Silvestris, N.; SOLIMANDO, A.G. Gene Expression Comparison Between the Lymph Node-Positive and Negative Reveals a Peculiar Immune-microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study. Preprints 2019, 2019060228 (doi: 10.20944/preprints201906.0228.v1).

Abstract

Over the past several years there has been much debate with regards to the prognostic and clinical significance of pancreatic ductal adenocarcinoma (PDAC) with lymph nodes metastasis. The PDAC gene-expression knowledge and the biologic alterations underlying the lymph node involvement convey a clinical implication in dealing with the theranostic window.To this end, we provide an original bioinformatic dissection of the gene-expression differences of PDAC according to the nodal involvement from a large public available dataset. Comprehensive transcriptomic analysis from 143 RNA-seq patient’s derived samples indicated that WNT increased activation and a peculiar immune-microenvironment identify subjects with nodal involvement.In frame of this thinking, we validated the WNT pathway role in increasing the likelihood of lymphatic dissemination in vitro. Moreover, we demonstrated for the first time in a PDAC model the potential therapeutic window that XAV-939, a specific WNT pathway inhibitor, has in re-educating a tumour permissive immune system. Finally, we outline the potential implication on bystander molecular drivers exerted by WNT molecular inhibition, providing a picture of the proteomic oncogenic landscape changes elicited by XAV-939 on PDAC cells and their clinical implication. Our findings hold the promise to identify novel immune-based therapeutic strategies targeting WNT to enhance PDAC cytotoxicity and restore anti-PDAC immunity in nodes-positive disease.

Subject Areas

pancreatic cancer; PDAC; lymph node metastases; WNT; dendritic cells; M2 macrophages; XAV-939; tumour immune-microenvironment

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.